Browsing Tag
tyrosine kinase inhibitors
2 posts
Why Enliven’s FDA alignment may matter as ELVN-001 moves toward Phase 3
Find out how Enliven’s ELVN-001 data and FDA alignment could reshape the next phase of chronic myeloid leukemia therapy.
Will CABOMETYX secure EU approval for advanced neuroendocrine tumors after CHMP’s positive opinion?
Ipsen’s CABOMETYX receives EMA's CHMP backing for advanced neuroendocrine tumors; EU approval expected in 2025 following FDA nod.